IGI Logo

Below are Quote on NATCO signs VLA for manufacture of Baricitinib by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd   

Natco Pharma Limited announced the signing of a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company, for the manufacture and commercialization of the drug Baricitinib for Covid-19 indication in India. In line with the licensing agreement, Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India. NATCO had earlier received an emergency use authorization for Baricitinib tablets, from Central Drugs Standard Control Organization (COSCO), for use in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). This is very positive news for Natco pharma while we need to consider the covid-19 2^nd wave is stable in India and cases have started coming down and positivity rate also come down.

Above views are of the author and not of the website kindly read disclaimer